Ascendis Pharma AS (MEX:ASND1N) Cyclically Adjusted Revenue per Share: MXN0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ASND1N Ascendis Pharma AS MEX:ASND1N
37 GF Score
Price MXN4,270.00
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted Revenue per Share?

Ascendis Pharma AS MEX:ASND1N 37 Cyclically Adjusted Revenue per Share is MXN0.00 as of Mar. 2026. GuruFocus rates MEX:ASND1N with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ascendis Pharma AS's adjusted revenue per share for the three months ended in Mar. 2026 was MXN79.677. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ascendis Pharma AS's average Cyclically Adjusted Revenue Growth Rate was 98.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-08), Ascendis Pharma AS's current stock price is MXN4270.00. Ascendis Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN0.00. Ascendis Pharma AS's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ascendis Pharma AS was 85.25. The lowest was 65.36. And the median was 75.22.


Ascendis Pharma AS  (MEX:ASND1N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ascendis Pharma AS was 85.25. The lowest was 65.36. And the median was 75.22.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ascendis Pharma AS Cyclically Adjusted Revenue per Share Related Terms


Ascendis Pharma AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted Revenue per Share Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:ASND1N vs BBIO, JAZZ, EXEL: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PS Ratio falls into.


MEX:ASND1N
37GF Score
Ascendis Pharma AS MEX:ASND1N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=79.677/121.6800*121.6800
=79.677

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.938 100.600 1.135
201609 1.007 100.200 1.223
201612 0.737 100.300 0.894
201703 0.231 101.200 0.278
201706 0.277 101.200 0.333
201709 0.288 101.800 0.344
201712 0.176 101.300 0.211
201803 0.016 101.700 0.019
201806 0.010 102.300 0.012
201809 0.010 102.400 0.012
201812 5.583 102.100 6.654
201903 2.736 102.900 3.235
201906 1.477 102.900 1.747
201909 1.025 102.900 1.212
201912 1.098 102.900 1.298
202003 1.201 103.300 1.415
202006 0.774 103.200 0.913
202009 1.361 103.500 1.600
202012 0.242 103.400 0.285
202103 0.338 104.300 0.394
202106 0.455 105.000 0.527
202109 0.493 105.800 0.567
202112 1.997 106.600 2.280
202203 2.640 109.900 2.923
202206 2.347 113.600 2.514
202209 5.454 116.400 5.701
202212 8.453 115.900 8.875
202303 11.556 117.300 11.988
202306 15.658 116.400 16.368
202309 15.868 117.400 16.446
202312 40.472 116.700 42.199
202403 30.411 118.400 31.253
202406 11.675 118.500 11.988
202409 21.967 118.900 22.481
202412 63.514 118.900 64.999
202503 37.202 120.200 37.660
202506 53.705 120.700 54.141
202509 75.708 121.600 75.758
202512 85.279 121.200 85.617
202603 79.677 121.680 79.677

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN0.00 mean?
Ascendis Pharma AS (MEX:ASND1N) has a Cyclically Adjusted Revenue per Share of MXN0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Cyclically Adjusted Revenue per Share too high?
Ascendis Pharma AS's current Cyclically Adjusted Revenue per Share is MXN0.00. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Cyclically Adjusted Revenue per Share compare to BBIO and JAZZ?
Ascendis Pharma AS's Cyclically Adjusted Revenue per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Cyclically Adjusted Revenue per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASND1N) has a current Cyclically Adjusted Revenue per Share of MXN0.00. The current Cyclically Adjusted Revenue per Share is MXN0.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASND1N), the current Cyclically Adjusted Revenue per Share is MXN0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASND1N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,270.00
Price